Cell-based high-throughput screens for the discovery of chemotherapeutic agents

Jennifer T Fox; Kyungiae Myung

doi:10.18632/oncotarget.513

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Cell-based high-throughput screens for the discovery of chemotherapeutic agents

Jennifer T Fox and Kyungiae Myung _

PDF | HTML | How to cite

Oncotarget. 2012; 3:581-585. https://doi.org/10.18632/oncotarget.513

Metrics: PDF 2450 views | HTML 2957 views | ?

Abstract

Jennifer T. Fox1¹ and Kyungjae Myung1¹

¹ Genome Instability Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Received: April 26, 2012; Accepted: May 29, 2012; Published: May 29, 2012;

Keywords: ATAD5-luciferase, genotoxins, DNA repair mutants, cancer, drug discovery

Correspondence:

Kyungjae Myung, email:

Abstract

With modern advances in robotics and data processing, high-throughput screening (HTS) is playing an increasingly growing role in the drug discovery process. The ultimate success of HTS depends upon the development of assays that are robust and reproducible in miniaturized formats, have low false-positive rates, and can identify drugs that offer improvements over those currently on the market. One example of such an assay is the ATAD5-luciferase HTS assay, which identified three antioxidants that could kill cancer cells without inducing mutagenesis. Here we discuss the ATAD5-luciferase assay and expand upon the value of HTS in identifying other potential cancer drugs, focusing on cell-based assays that involve DNA damage or repair pathways.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 513

Publication Alerts

Research Perspectives:

Cell-based high-throughput screens for the discovery of chemotherapeutic agents

Abstract